Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.

Elisabetta Patorno Chandrasekar GopalakrishnanKimberly G BrodoviczAndrea MeyersDorothee B BartelsJun LiuMartin KulldorffSebastian Schneeweiss

Published in: Diabetes, obesity & metabolism (2019)

Analyses from a large monitoring programme in routine care of patients with T2D, showed that linagliptin had similar CV safety compared to other DPP-4 inhibitors and pioglitazone, and a reduced CV risk compared to sulphonylureas.

Keyphrases

healthcare
palliative care
clinical practice
quality improvement
study protocol
pain management
affordable care act
type diabetes
blood pressure